Cost-Effectiveness Methods and Newborn Screening Assessment

Adv Exp Med Biol. 2017;1031:267-281. doi: 10.1007/978-3-319-67144-4_16.


Nowadays, health funding decisions must be supported by sound arguments in terms of both effectiveness and economic criteria. After more than half a century of newborn screening for rare diseases, the appropriate economic evaluation framework for these interventions is still challenging. The validity of standard methods for economic evaluation heavily relies on the availability of robust evidence, but collection of such evidence is precluded by the rareness of the conditions that may benefit from screening. Furthermore, there are a series of conceptual and methodological limitations that warrant further careful consideration when assessing the cost-effectiveness of newborn screening programs. In this chapter we provide a general overview of current economic evaluation methods and the challenges for their application to newborn screening programs.

Keywords: Newborn screening; Cost-effectiveness analysis; Cost-utility analysis; Economic evaluation; Biotinidase deficiency; Quality-adjusted life years.

Publication types

  • Review

MeSH terms

  • Biotinidase Deficiency / diagnosis
  • Biotinidase Deficiency / economics
  • Biotinidase Deficiency / therapy
  • Cost-Benefit Analysis
  • Health Care Costs*
  • Humans
  • Incidence
  • Infant, Newborn
  • Models, Economic
  • Neonatal Screening / economics*
  • Neonatal Screening / methods*
  • Predictive Value of Tests
  • Prevalence
  • Prognosis
  • Quality-Adjusted Life Years
  • Rare Diseases / diagnosis*
  • Rare Diseases / economics*
  • Rare Diseases / therapy